Mesio-Temporal Lobe Epilepsy (MTLE)
Also called Focal, Drug-refractory or Drug-resistant epilepsy, Mesio-Temporal Lobe Epilepsy (MTLE) is an epileptic condition for which no effective nor satisfactory treatment exists to date.
With over 10% of the total epileptic population affected, MTLE is a major challenge for patients as most pharmacological treatments have no effect on these seizures.
How about addressing the disease with a preclinical model that mimicks human MTLE?
clinically-relevant model of mtle
The MTLE mouse model is non-convulsive. Seizures are monitored within the brain and cannot be assessed without appropriate EEG methods.
Our MTLE model is the most reliable on the market. Model generation is standardized and perfectly mastered in-house.
Intra-hippocampal injection of kainic acid (kainate) sets the initial event for MTLE induction. Epileptogenesis phase starts and lasts for 3 to 4 weeks.
Animals then progressively show spontaneous and recurrent Hippocampal Paroxysmal Discharges (HPD), characteristic oscillatory bursts used as objective biomarker of drug-resistant seizures.
Compare your compound vs standard of care and demonstrate superior effect
We have validated the model-biomarker duo (MTLE mouse – HPD) by a pharmacology of reference and demonstrated a differential sensitivity to AEDs with a greater efficacy of drugs that facilitate GABAergic transmission. This is what makes the model a powerful tool to identify new treatments for drug-resistant forms of focal epilepsies.
Pr. Karen S. Wilcox, Chair of Pharmacology and Toxicology at University of Utah
We find in SynapCell a predictive rodent model of therapy-resistant MTLE that supplements our evaluation capabilities and addresses an important recommendation of the NINDS Working Group.
From HIT ID to LEAD Validation
Augmented by our EEG capabilities (Cue), you can use the MTLE model for several applications, including the screening of a small library of compounds, performing dose-response studies or assessing the disease-modifying potential of your compound on epileptogenesis (anti-epileptogenic effect). The model is also relevant to evaluate the potentiating or synergistic effects of an AED when combined to other drugs and identify the most effective drug associations.
Combine a MTLE study (focal epilepsy) with a GAERS study (generalized epilepsy) to derisk your compounds, identify seizure-aggravating effects and more importantly, align your preclinical strategy with your clinical roadmap to validate your AED.
join a complete program for your aed
Pathophysiological and electrical signalling underlying epileptic disorders have common grounds with several brain pathologies. Hypersynchrony of neurons are indeed also found in Alzheimer’s disease, Essential Tremor or Pain for example. As a consequence, Anti-Epileptic Drugs (AED) are today being used aside from epilepsy to treat different types of brain disorders like gabapentine or primidone used as a treatment for Essential Tremor.